The objective of this project is to evaluate the effectiveness of mesenchymal stem cells in the treatment of Chronic Inflammatory Diseases of the Intestine (Crohn's disease (CD) and ulcerative colitis (HCR)). MSAs have a threefold mechanism of action: - They have direct and indirect antibacterial effects - They modulate inflammation by adapting as a patient. Indeed, depending on the environment in which they are located, they will adapt their phenotype to modulate inflammation or, conversely, boost immunity. - They migrate to the aggrieved sites to have a remedial action of the aggrieved sites. These properties are extremely interesting in inflammatory and autoimmune pathologies. More specifically, the MEGUSTA project aims at the clinical validation in phase Ib of WhartSep®, a cell therapy drug developed and produced by StemInov, in patients with Chronic Inflammatory Diseases of the Intestine (Crohn's disease (CD) and ulcerative colitis (HCR) as well as the identification of a biological signature. It will allow the clinical validation of StemInov's production platform in the Great East in a second inflammatory indication and the creation of a European sector around the bioproduction of MSC-GW in this territory.